THOUSAND
OAKS, Calif., Nov. 2, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for
the investment community in conjunction with the American Heart
Association (AHA) Scientific Sessions at 6:00 p.m. ET on Monday, Nov. 7, 2022.
David M. Reese, M.D., executive vice
president of Research and Development at Amgen, along with members
of Amgen's R&D team and a clinical investigator, will discuss
the Phase 2 data on olpasiran, an investigational small interfering
RNA molecule designed to lower the body's production of
apolipoprotein(a), a key component of Lipoprotein(a), or Lp(a),
that has been associated with an increased risk of cardiovascular
events and data from the Repatha FOURIER and FOURIER-open label
extension studies.
Additionally, although no data are being presented at AHA, the
Company will provide an update on a Phase 1 study of AMG 133, a
multispecific molecule being developed for obesity, during the
call. The webcast will be broadcast over the internet
simultaneously and will be available to members of the news media,
investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences, can be found on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has
reached millions of patients around the world and is developing a
pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones
Industrial Average and is also part of the Nasdaq-100 index.
In 2021, Amgen was named one of the 25 World's Best Workplaces™ by
Fortune and Great Place to Work™ and one of the 100 most
sustainable companies in the world by Barron's.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Jessica Akopyan, 805-447-0974
(media)
Michael Strapazon, 805-313-5553
(media)
Arvind Sood, 805-447-1060
(investors)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-aha-2022-301666789.html
SOURCE Amgen